Seagen announces tukysa® (tucatinib) in combination with trastuzumab granted priority review by fda for previously treated her2-positive metastatic colorectal cancer

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced that the u.s. food and drug administration (fda) has accepted for priority review the supplemental new drug application (snda) seeking accelerated approval for tukysa® (tucatinib) in combination with trastuzumab for adult patients with her2-positive colorectal cancer who have received at least one prior treatment regimen for unresectable or metastatic disease. the snda submission is based on the results of the pivotal p
SGEN Ratings Summary
SGEN Quant Ranking